The company’s analysis of clinical research activity in the region shows the conflict will have long-lasting effects that reach beyond the country’s borders.
The latest news on software, manufacturing solutions, partnerships, and more includes IQVIA, TFF Pharmaceuticals, Quotient Sciences and other key companies.
The medication adherence specialist is joining IT4Anxiety, a project focused on dealing with anxiety in patients with mental disorders, via technology.
A leader from the patient recruitment specialist discusses the industry’s ongoing challenges with patient population diversity, and potential solutions.
While strides have been made recruiting more representative patient populations, more can and should be done, according to an Oracle Health Sciences leader.
A leader from the trial platform company discusses how patient experience can be enhanced when the clinical trial team shares a background with the subjects.
The Seeker Health digital patient enrollment platform is intended to help trial teams find patients from populations that are typically hard to connect with.
Cloud-based Clarify Trials is real-world evidence-based software intended to improve recruitment of clinical study patients from underrepresented communities.
The pharmaceutical company has announced 24 grants totaling nearly $8m USD to fuel training and support for community health workers and patient navigators.
An expert from the R&D tech provider discusses how automation, integration, and other tools can help with effective access and analysis of lab information.
With two decades of experience as a practicing psychiatrist, mdgroup medical director Arthur Lazarus offers broad experience and strong patient advocacy.
According to findings from Press Ganey, physicians and pharmaceutical company sites are the top resources patients turn to for information about medicines.
The US- and Hungary-based pharma firms will work on research, development, and commercialization of dopamine receptor modulators for potential treatments.
During Outsourcing-Pharma’s March 23 webinar, Clinical Development Advances, leaders from different areas will share innovative technology and practices.
The pharma company and academic institution will explore the viability of a psychedelic treatment to help patients suffering from cancer-related distress.
Patient-centric company Belong.life has developed an app designed to inform cancer research by offering a holistic view of the lives of people with cancer.
The pharma company is evaluating its Paxlovid oral treatment, intended for high-risk patients who have tested positive for the virus, in pediatric subjects.
A leader from the VCRO shares how far the industry has come with decentralized adoption, where opportunities for improvement exist, and what lies ahead.
Changing to DCT is more than merely flipping a switch; two leaders from the Thermo Fisher Scientific business offer advice for implementing the format.
A leader from the eClinical solutions provider talks about the unique considerations that cancer studies have at every stage, and how technological solutions can help address them.
The pharmaceutical company and the digital therapeutics specialist are joining forces to help accelerate the expansion of various digital health solutions.
The drug company has renewed its arrangement with the artificial intelligence specialist, centered on using AI to improve understanding of the immune system.
The pharma firm has allied with the biotech to create a scalable data, analytics, and infrastructure platform to generate insights from healthcare biobanks.
The two companies, along with Datavant, will combine real-world data and decentralized platforms to yield better patient information management and insights.
This month’s announcements include hiring, expansion, and acquisition news from companies like DFE Pharma, ClinOne, Novartis, LEGO, Benchling, and more.
Experts from the clinical tech firm talk data challenges and how monitoring technology can enable sites and sponsors to better manage audit trail reviews.
The company (which specializes in developing therapies for rare cancers) currently is working on a number of candidates, including its lead drug CPI-613.
The recent Outsourcing-Pharma webinar hosted a trio of industry experts highlighting challenges, opportunities, and innovations in the rare disease realm.
Ergomed, a global contract research organization, is partnering with Trialbee to improve patient recruitment at its new Rare Disease Innovation Center.
The AI-centered genomics company is joining with Don’t Forget Morgan, a group for patients with BPAN, to explore treatments for the neurodegenerative condition.
The pharmaceutical company’s Lilly Institute for Genetic Medicine reportedly will focus on developing RNA-based therapeutics in a ‘state-of-the-art’ facility.
In its latest diversity, equity and inclusion report, Global Genes offers insight into obstacles faced by rare-disease patients from minority communities.
The agency has given the go-ahead for a Phase I study of the company’s IO-202 antibody (in combination with Merck’s Keytruda) to treat various tumor types.
The two companies, which have been collaborating for 15 years, reportedly will focus on elevating decentralized trial solutions to develop new therapies.
The CRO is helping out on a project exploring the effects of the virus in children; other members of the research team include experts from Duke University.
On February 23, five days ahead of the day of rare-disease awareness, OSP’s Rare and Orphan Diseases webinar will share insights from top industry experts.
Created via a joint effort with EY, the pharmaceutical company launched ASPIREs, a program intended to improve its clinical trial processes in numerous areas.
In its forward-looking report on digital health, the consulting outfit offers predictions on what changes are ahead and how they might impact the field.
This month’s list of announcements about technology, funding, and more includes Medable, Clarify Health, Thermo Fisher Scientific, and other key companies.
According to a representative from the decentralized trial solutions company, the field of digital therapeutics is poised to gain significant popularity.
An expert from the institutional review board services company advises what trends to look for in the clinical trial industry over the course of coming months.
Cullinan Oncology has formed a strategic partnership with the Icahn School of Medicine at Mount Sinai to research and develop targeted therapies for cancer.
In this second of a two-part series, experts from the clinical research organization share thoughts on how data management technology, personnel, and partnerships have evolved.
In the first of a two-part series, leaders from the CRO discuss how study data has progressed in recent years and how trial teams can keep up effectively.
The pharmaceutical company, which uses thin-film freezing to develop inhalable therapies, has completed enrollment in the first phase for its drug candidate.
The company’s analysis of trials conducted around the world last year shows cancers took four of the top five positions, with COVID-19 in second place.
Vision, part of the company’s Clinical Maestro platform of software-as-a-solution applications, enables study teams to manage clinical vendor oversight.
The latest in the Diversity in Oncology series, taking place February 9, will discuss ways academia and community collaboration can narrow representation gaps.
The precision medicine company is joining with decentralized trial specialist Curebase to bring its cancer studies to a more diverse group of patients.
